Cullinan Therapeutics, Inc. (CGEM) NASDAQ
12.90
-0.94(-6.79%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
12.90
-0.94(-6.79%)
Currency In USD
Address
One Main Street
Cambridge, MA 02142
United States of America (the)
Phone
617 410 4650
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
111
First IPO Date
January 08, 2021
| Name | Title | Pay | Year Born |
| Nadim Ahmed | President, Chief Executive Officer & Director | 1.17M | 1968 |
| Mary Kay Fenton | Chief Financial Officer | 544,153 | 1964 |
| Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 763,734 | 1958 |
| Jeffrey Jones | Chief Medical Officer | 844,826 | 1971 |
| Corinne Savill | Chief Business Officer | 0 | 1959 |
| Jennifer Michaelson | Chief Scientific Officer | 0 | 1967 |
| Steve Andre | Chief Human Resources Officer | 0 | N/A |
| Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 0 | 1978 |
| Rose Weldon | Senior Vice President of Corporate Affairs | 0 | N/A |
| Nicholas Smith | Head of Investor Relations | 0 | N/A |
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.